Global Diabetic Retinopathy Market 2014-2018


◆タイトル:Global Diabetic Retinopathy Market 2014-2018
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆資料形式:pdf / 英語
Single UserUSD2,500 ⇒換算¥277,500見積依頼/購入/質問フォーム
Five UserUSD2,800 ⇒換算¥310,800見積依頼/購入/質問フォーム
Enterprise License(社内共有可)USD3,500 ⇒換算¥388,500見積依頼/購入/質問フォーム
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。



About DR and its Treatment Types
DR is defined as an eye disorder that damages the blood vessels of the retina. The retina is the light-sensitive inner surface of the eye which acts as a film for the formation of an image. Long-term diabetes affects the retina as a high blood glucose level can deteriorate and damage the tiny blood vessels in the retina. DR is broadly classified into either non-proliferative DR or proliferative retinopathy. Treatment for DR is dependent on the stage of the disease and is directed at trying to slow or stop the progression of the disease. At present, three types of treatment exist for DR: laser surgery, injection of corticosteroids or anti-VEGF drugs into the eye, and vitrectomy.
TechNavio’s analysts forecast the Global DR market will grow at a CAGR of 6.8 percent over the period 2013-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global DR market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various ophthalmic injections and drugs used in the treatment of DR.
TechNavio’s report, the Global DR Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global DR market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
Key Vendors
• Bayer AG
• F. Hoffmann-La Roche Ltd.
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals Inc.
• Valeant Pharmaceuticals International Inc.
Other Prominent Vendors

• Abbott Laboratories Ltd.
• Alcon Laboratories Inc.
• Alimera Sciences Inc.
• Allergan Inc.
• Ampio Pharmaceuticals Inc.
• Antisense Therapeutics Ltd.
• Bausch & Lomb Inc.
• BCN Peptides SA
• Boehringer Ingelheim GmbH
• Ferrosan Holding A/S
• iCo Therapeutics Inc.
• Isis Pharmaceuticals Inc.
• LPath Inc.
• Lupin Ltd.
• Novast Laboratories Ltd.
• OPKO Health Inc.
• Parexel International Corp.
• pSivida Corp.
• Quark Pharmaceuticals Inc.
• Sirnaomics Inc.
• Thrombogenics NV
• Torrent Pharmaceuticals Ltd.
• Vitreoretinal Technologies Inc.
Key Market Driver
• Increase in Prevalence of Diabetes.
• For a full, detailed list, view our report.
Key Market Challenge
• Lack of Accurate Diagnosis of the Disease.
• For a full, detailed list, view our report.
Key Market Trend
• Increase in Awareness of DR Treatment.
• For a full, detailed list, view our report.
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.


01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
Product Profiles
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Pipeline Snapshot
08. Rate of Incidence and Prevalence
08.1.1 America
08.1.2 Europe
08.1.3 APAC Region
09. Geographical Segmentation
09.1 DR Market in the Americas
09.1.1 Market Size and Forecast
09.2 DR Market in the EMEA Region
09.2.1 Market Size and Forecast
09.3 DR Market in the APAC Region
09.3.1 Market Size and Forecast
10. Buying Criteria
11. Market Growth Drivers
12. Drivers and their Impact
13. Market Challenges
14. Impact of Drivers and Challenges
15. Market Trends
16. Trends and their Impact
17. Vendor Landscape
17.1 Competitive Scenario
17.1.1 Key News
17.1.2 Mergers and Acquisitions
17.2 Market Share Analysis 2013
17.3 Other Prominent Vendors
17.4 Future Players Extected To Tap the DR Market
18. Key Vendor Analysis
19. Other Reports in this Series

List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global DR Market 2013-2018 (US$ million)
Exhibit 3: Global DR Market by Geographical Segmentation
Exhibit 4: DR Market in the Americas 2013-2018 (US$ million)
Exhibit 5: DR Market in the EMEA Region 2013-2018 (US$ million)
Exhibit 6: DR Market in the APAC Region 2013-2018 (US$ million)


Bayer AG, F. Hoffmann-La Roche Ltd., Novartis AG , Pfizer Inc., Regeneron Pharmaceuticals Inc., Valeant Pharmaceuticals International Inc. , Abbott Laboratories Ltd., Alcon Laboratories Inc., Alimera Sciences Inc., Allergan Inc., Ampio Pharmaceuticals Inc., Antisense Therapeutics Ltd., Bausch & Lomb Inc., BCN Peptides SA, Boehringer Ingelheim GmbH, Ferrosan Holding A/S, iCo Therapeutics Inc., Isis Pharmaceuticals Inc., LPath Inc., Lupin Ltd., Novast Laboratories Ltd., OPKO Health Inc., Parexel International Corp., pSivida Corp., Quark Pharmaceuticals Inc., Sirnaomics Inc., Thrombogenics NV, Torrent Pharmaceuticals Ltd., Vitreoretinal Technologies Inc.



★調査レポート[グローバルにおける糖尿病網膜症治療市場(2014-2018)] (Global Diabetic Retinopathy Market 2014-2018 / IRTNTR3529)販売に関する免責事項
[グローバルにおける糖尿病網膜症治療市場(2014-2018)] (Global Diabetic Retinopathy Market 2014-2018 / IRTNTR3529)についてEメールでお問い合わせ